Characterization of pneumococcal serotype 7F in vaccine conjugation.
Dynamic light scattering (DLS)
Multi-angle light scattering (MALS)
Pneumococcal capsular polysaccharide 7F
Pneumococcal conjugate vaccine
Size-exclusion chromatography (SEC)
Ultra-performance liquid chromatography (UPLC)
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
03
04
2023
accepted:
14
06
2023
revised:
09
06
2023
medline:
13
11
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Streptococcus pneumoniae is a highly invasive bacterial pathogen that can cause a range of illnesses. Pneumococcal capsular polysaccharides (CPS) are the main virulence factors that causes invasive pneumococcal disease (IPD). Pneumococcal CPS serotype 7F along with a few other serotypes is more invasive and likely to cause IPD. Therefore, 7F is a target for pneumococcal vaccine development, and is included in the two recently approved multi-valent pneumococcal conjugated vaccines, i.e. VAXNEUVANCE and PREVNAR 20.To support process and development of our 15-valent pneumococcal conjugated vaccine (PCV15), chromatographic methods have been developed for 7F polysaccharide and conjugate characterization. A size-exclusion chromatography (SEC) method with UV, light scattering and refractive index detections was employed for concentration, size and conformation analysis. A reversed-phase ultra-performance liquid chromatography (RP-UPLC) method was used for analysis of conjugate monosaccharide composition and degree of conjugation. The collective information obtained by these chromatographic analysis provided insights into the pneumococcal conjugate and conjugation process.
Identifiants
pubmed: 37402017
doi: 10.1007/s10719-023-10125-8
pii: 10.1007/s10719-023-10125-8
pmc: PMC10638203
doi:
Substances chimiques
Pneumococcal Vaccines
0
Vaccines, Conjugate
0
Antigens, Bacterial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-573Informations de copyright
© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
Références
Vaccine. 2018 Oct 29;36(45):6883-6891
pubmed: 30244873
Vaccine. 2010 Jul 19;28(32):5167-73
pubmed: 20558247
Expert Rev Vaccines. 2021 Mar;20(3):243-256
pubmed: 33478306
Anal Biochem. 2000 Mar 15;279(2):226-40
pubmed: 10706792
Clin Microbiol Infect. 2014 Jul;20(7):684-9
pubmed: 24467648
Vaccine. 2011 Sep 22;29(41):7207-11
pubmed: 21689707
Anal Biochem. 2001 Dec 15;299(2):136-46
pubmed: 11730335
Nat Rev Microbiol. 2018 Jun;16(6):355-367
pubmed: 29599457
Vaccine. 2021 Dec 17;39(51):7494-7502
pubmed: 34839993
Anal Biochem. 2005 Dec 15;347(2):262-74
pubmed: 16266683
J Pharm Biomed Anal. 2000 Jan;21(6):1087-91
pubmed: 10708393
Vaccine. 2009 Oct 30;27(46):6468-70
pubmed: 19555714
Chemistry. 2018 Mar 15;24(16):4181-4187
pubmed: 29333751
Vaccine. 2022 Mar 1;40(10):1464-1471
pubmed: 35140014
Carbohydr Res. 1988 Oct 15;182(1):79-99
pubmed: 3149544
Glycoconj J. 2023 Apr;40(2):135-148
pubmed: 36652051
Carbohydr Res. 1993 Apr 23;243(1):115-30
pubmed: 8324758
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
NPJ Vaccines. 2023 Jan 23;8(1):2
pubmed: 36690697
Polymers (Basel). 2022 Sep 09;14(18):
pubmed: 36145915